Is Desh Rakshak overvalued or undervalued?

As of 6 November 2025, Desh Rakshak's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 27.87, an EV to EBITDA of 12.83, and a PEG ratio of 1.33, which suggest that the company is positioned favorably compared to its peers. In comparison to notable competitors, Desh Rakshak's PE ratio is lower than Sun Pharma's 35.02 and Divi's Lab's 79.09, both of which are categorized as expensive. Additionally, its EV to EBITDA ratio is more favorable than that of Torrent Pharma, which stands at 32.03. Despite recent stock performance showing a decline of 18.51% over the past week, Desh Rakshak has outperformed the Sensex significantly over the longer term, with a year-to-date return of 115.45% compared to the Sensex's 6.62%. This reinforces the view that the company is currently undervalued in the market.